p u b l i c a t i o n s
21. Matosin N, Cruceanu C. Stress-related memory impairments are modulated by the synergistic action of stress hormones: implications for PTSD. The Journal of Neuroscience. Accepted March 16 2017. In press. [5.924]
20. Matosin N, Newell KA, Quidé Y, Teroganova N, Andrews JL, Green MJ, Fernandez-Enright F. Effects of common GRM5 genetic variants on cognition, hippocampal volume and mGluR5 protein levels in schizophrenia. Brain Imaging and Behavior. Accepted March 19 2017. In press. [IF=3.667]
19. Matosin N, Green MJ, Newell KA, Fernandez-Enright F. Effects of GRASP variation on memory in psychiatrically healthy individuals and cognitive dysfunction in schizophrenia. Gene Reports [no IF]. 2017. 6: 121-127.
18. Matosin N, Siegel SJ. mGluR5 as a point of Convergence for models of OCD and ASD. Biological Psychiatry. 2016 80:7,504–506 [IF=11.212]
17. Matosin N, Fernandez-Enright F, Lum JS, Engel M, Andrews JL, Gassen NC, Wagner KV, Schmidt MV, Newell KA. Molecular evidence of synaptic pathology in CA1 in schizophrenia. npj Schizophrenia. 2016. 2: 16022
16. Lum JS, Fernandez F, Matosin N, Andrews JL, Huang XF, Ooi L, Newell KA. Neurodevelopmental expression of dimeric and monomeric group 1 mGluRs: relevance to schizophrenia pathogenesis and treatment. Scientific Reports. 2016 6: 34391. [IF=5.578]
15. Matosin N, Fernandez-Enright F, Lum JS, Newell KA. Shifting towards a model of mGluR5 dysregulation in schizophrenia: consequences for future schizophrenia treatment. Invited review, special Issue: “mGluRs: 5 years on”. Neuropharmacology. 2015. In press. [IF=5.106]
14. Matosin N, Green MJ, Andrews JL, Newell KA, Fernandez-Enright F. Possibility of a sex-specific role for a genetic variant in FRMPD4 in schizophrenia, but not cognitive function. Neuroreport. 2016. 27(1): 33-8. [IF=1.644]
13. Andrews JL, Goodfellow F, Matosin N, Snelling MK, Newell KA, Huang XF, Fernandez-Enright F. Alterations of Ubiquitin Related Proteins in the Pathology and Development of Schizophrenia: Evidence from Human and Animal Studies. Journal of Psychiatric Research. 2017. 90:31-39 [IF=4.465]
12. Engel M, Snikeris P, Matosin N, Newell KA, Huang XF, Frank E. mGluR2/3 agonist LY379268 rescues NMDA and GABAA receptor level deficits induced in a two-hit mouse model of schizophrenia. Psychopharmacology. 2016. 233(8): 1349-1359. [IF=3.875]
11. Matosin N, Fernandez-Enright F, Fung SJ, Lum JS, Engel M, Andrews JL, Huang XF, Weickert CS, Newell KA. Alterations of mGluR5 and its endogenous regulators Norbin, Tamalin and Preso1 in schizophrenia: towards a model of mGluR5 dysregulation. Acta Neuropathologica. 2015. 130(1): 119-129. [IF=10.762]
10. Matosin N, Fernandez-Enright F, Lum JS, Andrews JL, Engel M, Huang XF, Newell KA. Metabotropic glutamate receptor 5 and its trafficking molecules, Norbin and Tamalin, are increased in the CA1 hippocampal region of subjects with schizophrenia. Schizophrenia Research. 2015. 166(1-3): 212-218. [IF=4.590]
9. Wagner KV, Hartmann J, Labermaier C, Häusl AS, Zhao G, Harbich D, Schmid B, Wang X D, Santarelli S, Kohl C, Gassen NC, Matosin N, Schieven M, Webhofer C, Turck CW, Lindemann L, Jaschke G, Wettstein JG, Rein T, Müller MB, Schmidt MV. Homer1/mGluR5 signaling moderates vulnerability to chronic social stress. Neuropsychopharmacology. 2015. 40(5): 1222-1233. [IF=7.833]
8. Andrews JL, Newell KA, Matosin N, Huang XF, Fernandez-Enright F. Alterations of p75 neurotrophin receptor and myelin transcription factor 1 in the hippocampus of perinatal phencyclidine treated rats. Progress in Neuro-Psychopharmacology & Biological Psychiatry. 2015. 63(3): 91-97. [IF=3.689]
7. Andrews JL, Newell KA, Matosin N, Huang XF, Fernandez-Enright F. NMDA receptor antagonism by phencyclidine reduces WASP and WAVE1 protein expression and reduces levels of myelination marker levels in the prefrontal cortex of rats. Journal of Pharmaceutics & Pharmacology. 2015. 3(1):8. [IF=2.264]
6. Matosin N, Fernandez-Enright F, Frank L, Deng C, Wong J, Huang XF, Newell KA. Metabotropic glutamate receptor mGluR2/3 and mGluR5 binding in the anterior cingulate cortex in psychotic and non-psychotic depression, bipolar disorder and schizophrenia: implications for novel mGluR-based therapeutics. Journal of Psychiatry & Neuroscience. 2014. 39(6): 407-16. [IF=7.492]
5. Matosin N, Frank E, Engel M, Lum JS, Newell KA. EDITORIAL Negativity towards negative results: a discussion of the disconnect between scientific worth and scientific culture. Disease Models & Mechanisms. 2014. 7(2): 171-173. [IF=5.537]
4. Newell KA, Matosin N. Rethinking metabotropic glutamate receptor 5 pathological findings in psychiatric disorders: implications for the future of novel therapeutics. BMC Psychiatry. 2014. 14:23. [IF = 2.237]
3. Newell KA, Matosin N, Lum JS. BOOK CHAPTER Metabotropic glutamate receptors in the pathophsyiology and treatment of schizophrenia and major depression (book chapter). Metabotropic Glutamate Receptors: Molecular Mechanisms, Role in Neurological Disorders and Pharmacological Effects. Nova Publishers. 2014. ISBN: 978-1-63117-451-3
2. Matosin N and Newell KA. Metabotropic Glutamate Receptor 5 in the Pathology and Treatment of Schizophrenia. Neuroscience & Biobehavioural Reviews. 2013. 37 (3): 256-268. [IF = 10.284]
1. Matosin N, Frank E, Deng C, Huang XF, Newell KA. Metabotropic Glutamate Receptor 5 Binding and Protein Expression in Schizophrenia and following Antipsychotic Drug Treatment. Schizophrenia Research. 2013. 146 (1-3): 170-176. [IF=4.590]
- Positives in negative results: when finding ‘nothing’ means something. The Conversation, September 2014.
- Data Overload? Macro vs Micro Science. UOW Research, November 2013.